Nepavon-CS Eye Drop BAK Free
By Nepavon-CS
Rx
5ml Eye Drop in a Bottle

Composition
Nepafenac(0.1% w/v)

Manufacturer - Neomedix Healthcare India Private Limited
Plot No. -13 , Sector -5, Industrial Area, Parwanoo, Distt. Solan (H.P) India

Expires on or after
June, 2027

liver
When using Nepavon-CS Eye Drop BAK Free, there have been no interactions or issues with the liver reported or established. This means that it is generally safe to use the eye drops without any specific concerns related to liver health. However, it is always a good idea to consult with your doctor for proper guidance before using any medication, including Nepavon-CS Eye Drop BAK Free, especially if you have underlying liver conditions or concerns. Your doctor can provide personalized advice and ensure that the medication is safe for you to use.

kidney
No interaction has been found or established regarding Nepavon-CS Eye Drop BAK Free and kidney issues. Consult with your doctor for proper guidance before using Nepavon-CS Eye Drop BAK Free.

alcohol
No interaction has been found between Nepavon-CS Eye Drop BAK Free and alcohol. Therefore, it is safe to consume alcohol while using Nepavon-CS Eye Drop BAK Free.

driving
Nepavon-CS Eye Drop BAK Free may cause temporary vision blurring, so it is advisable to avoid driving until your vision is clear.

pregnancy
Nepavon-CS Eye Drop BAK Free is considered unsafe during pregnancy. Animal studies suggest potential harm to the developing baby. Your doctor will evaluate the benefits and risks before prescribing. Consult your doctor before using Nepavon-CS Eye Drop BAK Free during pregnancy.

breastfeeding
It is better to consult your doctor before using Nepavon-CS Eye Drop BAK Free during breastfeeding.
| Habit Forming | No |
| Chemical Class | Benzophenone Derivatives |
| Therapeutic Class | OPHTHAL |
| Action Class | NSAID's- Non-Selective COX 1&2 Inhibitors (Topical) |
₹250.75
₹295
15% OFF
Inclusive of all taxes
Content verified by

Dr. Archana Prabhakar
MBBS, M.Med (Family Medicine)
Last update on 18-Nov-2024
